Journal Links & Out-Takes
from Rockwell article
- Lew Rockwell.com, July 29, 2009
Paradox of vaccination: is vaccination really effective against avian flu epidemics? (PLoS One 4(3):e4915, March 18, 2009)
"Results show that a vaccination to prevent the spread of disease can instead spread the disease when the resistant strain is less virulent than the sensitive strain. If the loss is high, the program does not prevent the spread of the resistant strain despite a large prevalence rate of the program. The epidemic's final size can be larger than that before the vaccination program."
Modeling the effects of drug resistant influenza virus in a pandemic (Virology Journal 5: 133-39, 2008)
"Non-pharmaceutical interventions considered by health decision makers and occupational medicine specialists in their pandemic preparedness plans may play a crucial role."
Oseltamivir-Resistant Influenza Virus A (H1N1) (Emerging Infectious Diseases 15: 552-60, April 2009)
"the emergence of natural resistance [to oseltamivir (Tamiflu), an anti-viral medication]"
Antiviral prophylaxis during pandemic influenza may increase drug resistance (BMC Infectious Diseases 9: 4-12, January 2009)
"If the fitness of the NI resistant pandemic strain is high, any use of prophylaxis may increase the number of hospitalizations and deaths in the population. Thus, public health systems should diversify intervention strategies by using prophylaxis in a very restrictive manner, by stockpiling different types of antiviral drugs and by supplementing pharmaceutical interventions with social distancing measures.
Note: Neuraminidase inhibitors (NI) are a class of antiviral drugs targeted at the influenza viruses, such as Tamiflu and Relenza.
Antiviral resistance during pandemic influenza: implications for stockpiling and drug use (BMC Infectious Diseases 9: 8, January 22, 2009)
"[M]oderate to high treatment levels can result in a more rapid depletion of stockpiles, leading to run-out, by promoting wide-spread drug resistance....Our results show that if high treatment levels are enforced too early during the outbreak, a second wave of infections can potentially occur with a substantially larger magnitude."
"Baxter: Product contained live bird flu virus" (The Canadian Press February 27, 2009)
"The company that released contaminated flu virus material from a plant in Austria confirmed Friday that the experimental product contained live H5N1 avian flu viruses."
Baxter Healthcare Corporation Patent (US patent: US 2009/0060950 A1-Filed August 28, 2008; published March 5, 2009)
"A method for the manufacture of a preparation comprising virus antigens comprising (a) inoculation of cells with infectious virus in a fluid"
Targeting cell signalling pathways to fight the flu: towards a paradigm change in anti-influenza therapy (Journal Antimicrobial Chemotherapy 2009 July; 64(1):1-4)
"While in clinical trials of oseltamivir [Tamiflu] in seasonal influenza only a low percentage of resistance has been reported,7 much more worrying rates have been detected in a smaller study in Japanese children where 18% of all isolates were resistant.8 Since then, the number of reports on insensitivity to oseltamivir has rapidly increased, including findings on the emergence of influenza B viruses as well as H5N1 influenza A viruses that are resistant to the drug.
Naturally occurring NF-kappaB inhibitors (Mini Review Medicinal Chemistry 2006 Aug; 6(8):945-51)
"Play critical roles in controlling most inflammatory processes"
Citizens' Council on Health Care is a non-profit, independent health care policy organization that supports free-market ideas in health care.